JP2023539247A5 - - Google Patents

Info

Publication number
JP2023539247A5
JP2023539247A5 JP2023513299A JP2023513299A JP2023539247A5 JP 2023539247 A5 JP2023539247 A5 JP 2023539247A5 JP 2023513299 A JP2023513299 A JP 2023513299A JP 2023513299 A JP2023513299 A JP 2023513299A JP 2023539247 A5 JP2023539247 A5 JP 2023539247A5
Authority
JP
Japan
Prior art keywords
feline
seq
fusion protein
sequence
vector according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539247A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/047403 external-priority patent/WO2022046809A1/en
Publication of JP2023539247A publication Critical patent/JP2023539247A/ja
Publication of JP2023539247A5 publication Critical patent/JP2023539247A5/ja
Priority to JP2026035302A priority Critical patent/JP2026115041A/ja
Pending legal-status Critical Current

Links

JP2023513299A 2020-08-24 2021-08-24 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用 Pending JP2023539247A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026035302A JP2026115041A (ja) 2020-08-24 2026-03-05 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069492P 2020-08-24 2020-08-24
US63/069,492 2020-08-24
PCT/US2021/047403 WO2022046809A1 (en) 2020-08-24 2021-08-24 Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026035302A Division JP2026115041A (ja) 2020-08-24 2026-03-05 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用

Publications (2)

Publication Number Publication Date
JP2023539247A JP2023539247A (ja) 2023-09-13
JP2023539247A5 true JP2023539247A5 (cg-RX-API-DMAC7.html) 2024-09-02

Family

ID=80355670

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023513299A Pending JP2023539247A (ja) 2020-08-24 2021-08-24 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用
JP2026035302A Pending JP2026115041A (ja) 2020-08-24 2026-03-05 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026035302A Pending JP2026115041A (ja) 2020-08-24 2026-03-05 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用

Country Status (8)

Country Link
US (1) US20230405150A1 (cg-RX-API-DMAC7.html)
EP (1) EP4199942A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023539247A (cg-RX-API-DMAC7.html)
KR (1) KR20230054419A (cg-RX-API-DMAC7.html)
CN (1) CN116390745A (cg-RX-API-DMAC7.html)
AU (1) AU2021332232A1 (cg-RX-API-DMAC7.html)
CA (1) CA3190396A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022046809A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026039341A1 (en) 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039359A1 (en) 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039340A1 (en) 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
CN120005002B (zh) * 2025-04-22 2025-07-25 西宝生物科技(上海)股份有限公司 一种glp-1类似物的生物发酵制备方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
CA2833623A1 (en) * 2011-04-20 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
WO2017024198A1 (en) * 2015-08-06 2017-02-09 The Trustees Of The University Of Pennsylvania Glp-1 and use thereof in compositions for treating metabolic diseases
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2018318440A1 (en) * 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
WO2020139984A1 (en) * 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Igg fc variants for veterinary use

Similar Documents

Publication Publication Date Title
JP2020510428A5 (cg-RX-API-DMAC7.html)
JP2022513308A5 (cg-RX-API-DMAC7.html)
JP2023518596A5 (cg-RX-API-DMAC7.html)
JP2023503637A5 (cg-RX-API-DMAC7.html)
JP2023506765A5 (cg-RX-API-DMAC7.html)
JP2020510430A5 (cg-RX-API-DMAC7.html)
JP2020519292A5 (cg-RX-API-DMAC7.html)
JP2018537984A5 (cg-RX-API-DMAC7.html)
RU2010100913A (ru) Слитые белки rage
FI4206216T3 (fi) Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi
JP2022547197A5 (cg-RX-API-DMAC7.html)
JP2011525363A5 (cg-RX-API-DMAC7.html)
ES3063491T3 (en) Treatment of ocular neovascular diseases using aav2 variants encoding aflibercept
JP7840319B2 (ja) Glp-1受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用
JP2022520232A5 (cg-RX-API-DMAC7.html)
JP7654562B2 (ja) 線維芽細胞増殖因子23関連低リン血症性疾患の遺伝子療法
JP2023535121A5 (cg-RX-API-DMAC7.html)
MX2024009478A (es) Métodos para tratar enfermedades neovasculares oculares con variantes de aav2 que codifican aflibercept
JP2023539247A (ja) Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用
JP2023542453A5 (cg-RX-API-DMAC7.html)
JP2023540599A5 (cg-RX-API-DMAC7.html)
JP2025518052A5 (cg-RX-API-DMAC7.html)
JP2021521782A5 (cg-RX-API-DMAC7.html)
MX2022002960A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
US20250171515A1 (en) Aav vectors for delivery of glp-1 receptor agonist fusions